dotMD.com
✓ Translated by DotMD AI Clinical Council Source: Cardiovascular revascularization medicine : including molecular interventions • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #27919638 ↗

Can This Approach Help? Inside the Latest Research on Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque

Original Paper Title: “Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • What Researchers Found: Published in heart and blood vessel revascularization medicine : including molecular interventions (2017), this randomized controlled trial evaluating human clinical outcomes investigated: The aim of this study was to examine the influence of ezetimibe in addition to atorvastatin on plaque composition in patients with first-time ST-segment Elevation heart attack treated with primary percutaneous intervention.
  • Who Was Studied: Randomized Controlled Trial published in Cardiovascular revascularization medicine : including molecular interventions following multiple clinical patient cohorts.
  • Strength of the Evidence: Earned a 88/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.

What the Study Found (In Plain English)

### Why This Matters to You When you or someone you love is weighing a health decision, medical journals can feel like they are written in a secret code. Yet buried inside those dense reports are practical answers that can help you feel better, avoid unnecessary side effects, and ask smarter questions at your next checkup. That is why a randomized controlled trial published in *Cardiovascular revascularization medicine : including molecular interventions* caught our clinical team's attention. ### What the Researchers Looked At In this study, researchers set out to answer a straightforward question: influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with st-segment elevation heart attack assessed by serial: intravascular ultrasound with imap: the octivus trial. To get reliable answers, the team evaluated multiple clinical patient cohorts using a randomized controlled trial design—one of the most trusted ways doctors test whether a treatment truly works or is just a fluke. ### What the Study Found in Plain English Published in heart and blood vessel revascularization medicine : including molecular interventions (2017), this randomized controlled trial evaluating human clinical outcomes investigated: The aim of this study was to examine the influence of ezetimibe in addition to atorvastatin on plaque composition in patients with first-time ST-segment Elevation heart attack treated with primary percutaneous intervention. Key clinical takeaway: Ezetimibe in addition to atorvastatin therapy did not influence NC content, but was associated with regression of coronary atherosclerosis Instead of relying on guesswork, this randomized controlled trial gives patients and doctors concrete evidence they can weigh together. ### The Catch: What to Keep in Mind Even strong medical studies have limits. Every person's body processes medicines and lifestyle changes differently based on age, genetics, kidney and liver health, and other prescriptions in their cabinet. What worked on average in a research setting may need a tailored dose—or a different option altogether—for you. ### Bottom Line: Your Next Step Bring this summary to your next doctor or pharmacist visit. Ask: *"Based on my health history and current medications, does this research apply to me—and is there anything we should adjust?"* You can also click the formal study link below to inspect the original peer-reviewed paper directly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in Cardiovascular revascularization medicine : including molecular interventions (2017-03-15) • Study Design: Randomized Controlled Trial • Participants: Pooled Clinical Review • Biostatistical Rigor Score: 88/100. Key Finding: Published in heart and blood vessel revascularization medicine : including molecular interventions (2017), this randomized controlled trial evaluating human clinical outcomes investigated: The aim of this study was to examine the influence of ezetimibe in addition to atorvastatin on plaque composition in patients with first-time ST-segment Elevation heart attack treated with primary percutaneous intervention.

Study Limitations & Caveats Before You Act

While this randomized controlled trial scored 88/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 27919638: Can This Approach Help? Inside the Latest Research on Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque

3 of 3 Free Questions Remaining